TWIST1 and cancer: CTCs with the expression of mesenchymal markers, like TWIST1, SNAIL1, or vimentin were more likely to be identified in patients with advanced cancer compared to those with early-stage cancer, suggesting the potential role in metastatic dissemination and disease progression (8).